Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Neoplasm Metastasis 2Leukemia 2Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Histamine × Clear all
NCT05810792 2023-11-22

PANCEP-1

Sahlgrenska University Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00039234 2013-12-18

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

National Cancer Institute (NCI)

Phase 3 Unknown
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡